Alembic Pharma raises Rs 350 crore via NCDs
“The NCD committee of Alembic Pharma…Has allotted 1,500, 9 per cent rated unsecured listed redeemable non-convertible debentures (NCDs)… Aggregating to Rs 150 crore under tranche I,” Alembic Pharmaceuticals said in a regulatory filing.
NEW DELHI: Drug firm Alembic Pharma recently said it has raised Rs 350 crore through allotment of non-convertible debentures (NCDs) on private placement basis.
“The NCD committee of Alembic Pharmaceuticals Ltd…Has allotted 1,500, 9 per cent rated unsecured listed redeemable non-convertible debentures (NCDs)… Aggregating to Rs 150 crore under tranche I,” Alembic Pharmaceuticals said in a regulatory filing.
The company said it has also allotted 2,000, 9 per cent rated unsecured listed redeemable NCD aggregating to Rs 200 crore.
Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara city of Gujarat. Alembic Pharmaceuticals Ltd. is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates.
Also Read: Alembic Pharma plans to get upto Rs 500 crore through NCDs
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd